Larimar Therapeutics(LRMR) - 2023 Q4 - Annual Results

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development Bala Cynwyd, PA, March 14, 2024 – Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2023 operating and financial results. "This year we made tremendous progress across key clinical and regulatory milestones for our nom ...